226 related articles for article (PubMed ID: 15497681)
1. Identification of biowaivers among Class II drugs: theoretical justification and practical examples.
Rinaki E; Dokoumetzidis A; Valsami G; Macheras P
Pharm Res; 2004 Sep; 21(9):1567-72. PubMed ID: 15497681
[TBL] [Abstract][Full Text] [Related]
2. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio.
Rinaki E; Valsami G; Macheras P
Pharm Res; 2003 Dec; 20(12):1917-25. PubMed ID: 14725354
[TBL] [Abstract][Full Text] [Related]
3. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
4. Biopharmaceutic classification of drugs revisited.
Daousani C; Macheras P
Eur J Pharm Sci; 2016 Dec; 95():82-87. PubMed ID: 27496048
[TBL] [Abstract][Full Text] [Related]
5. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS).
Fagerholm U
J Pharm Pharmacol; 2007 Jun; 59(6):751-7. PubMed ID: 17637167
[TBL] [Abstract][Full Text] [Related]
6. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
7. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
8. The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs.
Yazdanian M; Briggs K; Jankovsky C; Hawi A
Pharm Res; 2004 Feb; 21(2):293-9. PubMed ID: 15032311
[TBL] [Abstract][Full Text] [Related]
9. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
10. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
Davit BM; Kanfer I; Tsang YC; Cardot JM
AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
[TBL] [Abstract][Full Text] [Related]
11. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
[TBL] [Abstract][Full Text] [Related]
12. Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage.
Miyaji Y; Fujii Y; Takeyama S; Kawai Y; Kataoka M; Takahashi M; Yamashita S
Mol Pharm; 2016 May; 13(5):1564-74. PubMed ID: 27031624
[TBL] [Abstract][Full Text] [Related]
13. Biopharmaceutics classification system: the scientific basis for biowaiver extensions.
Yu LX; Amidon GL; Polli JE; Zhao H; Mehta MU; Conner DP; Shah VP; Lesko LJ; Chen ML; Lee VH; Hussain AS
Pharm Res; 2002 Jul; 19(7):921-5. PubMed ID: 12180542
[TBL] [Abstract][Full Text] [Related]
14. A reaction limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs.
Macheras P; Iliadis A; Melagraki G
Eur J Pharm Sci; 2018 May; 117():98-106. PubMed ID: 29425862
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
16. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test.
Takano R; Sugano K; Higashida A; Hayashi Y; Machida M; Aso Y; Yamashita S
Pharm Res; 2006 Jun; 23(6):1144-56. PubMed ID: 16715363
[TBL] [Abstract][Full Text] [Related]
17. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted.
Benet LZ; Larregieu CA
Clin Pharmacol Ther; 2010 Sep; 88(3):405-7. PubMed ID: 20668447
[TBL] [Abstract][Full Text] [Related]
18. The developability classification system: application of biopharmaceutics concepts to formulation development.
Butler JM; Dressman JB
J Pharm Sci; 2010 Dec; 99(12):4940-54. PubMed ID: 20821390
[TBL] [Abstract][Full Text] [Related]
19. A non-binary biopharmaceutical classification of drugs: the ABΓ system.
Macheras P; Karalis V
Int J Pharm; 2014 Apr; 464(1-2):85-90. PubMed ID: 24456673
[TBL] [Abstract][Full Text] [Related]
20. The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations.
Corrigan OI
Adv Exp Med Biol; 1997; 423():111-28. PubMed ID: 9269487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
